Provectus Receives Guidance From FDA On Pathway to Approval for Phase 3 Trial of PV-10 For Metastatic Melanoma
Dr. Craig Dees talks candidly in a live audio interview about the company’s developments.
2481
Provectus Pharmaceuticals Uses Old Drug To Actualize Novel Therapeutics for Cancer and Skin Disorders
Provectus Pharmaceuticals develops a powerful drug pipeline with minimal side effects, including a cancer drug that targets cancer tissue, as well as…
NYSSA Announces Presenter List for Upcoming Biotech Conference
The New York Society of Security Analysts, a leading forum for the investment community, recently announced the presenter list for its 14th Annual Biotech and Specialty Pharma Conference.
Oculus Innovative Sciences to Collaborate with Onset Therapeutics
Their initial collaboration will target atopic dermatitis and related conditions.
Provectus Reports Positive Preliminary Data for Dermatology Drug
Patients with psoriasis demonstrated 79% improvement in the Psoriasis Scoring Index after four weeks of daily treatment with PH-10.